**Contents**

Volume 80 Issue 1 | ARD January 2021

**Editorials**

1. Greetings from the editor 2021
   
   J S Smolen

3. COVID-19 cytokine storm: what is in a name?
   
   P A Nigrovic

**Views on news**

6. The role of TASL in the pathogenesis of SLE: X marks the spot
   
   D S Pisetsky

**Heroes and pillars of rheumatology**

   
   B Manger, G Schett

**Thinking the unthinkable**

11. Publishing in 2@84
   
   M Lanzilotta, C Creni, V M Da Silva Domingues, K Lauper, G R Burmester

**Review**

14. Update on the diagnosis and management of systemic lupus erythematosus
   
   A Fanourakis, N Tziolos, G Bertsias, D T Boumpas

**Recommendations**

31. EULAR definition of difficult-to-treat rheumatoid arthritis
   

EULAR recommendations for a core data set for pregnancy registries in rheumatology


2019 EULAR points to consider for non-physician health professionals to prevent and manage fragility fractures in adults 50 years or older


2019 EULAR points to consider for the assessment of competences in rheumatology

J Schmitt, J Zink, D Bakkers, E WJ Bijlsma, M Rodríguez-García, S Wallenius, M Tziolos, C van der Goes, A Månsen, T WJ Bijlsma, K van der Laar, N Vassilopoulos, C Haines, S Ramiro

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement


EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors


**Annals of the Rheumatic Diseases**

Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

WC1H 9JR London

Copyright and Disclaimer

The Editor of ARD has granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD, Neither BMJ nor the Journal can nor liability cannot legally excluded.

© 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd and is made freely available online under the BMJ Journals open access scheme. This article has been made freely available online under the BMJ Journals open access scheme. See http://authors.bmj.com/open-access/
Rheumatoid arthritis
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Spondyloarthritis
Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine
T Renson, P Carron, A S De Cenmer, I Deroo, M de Hooge, S Kraakh, I Janz, M Chen, M Østergaard, F E Van den Bosch, D Elewaat

Systemic lupus erythematosus
Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing

Systemic sclerosis
Genomic Risk Score impact on susceptibility to systemic sclerosis

Autoinflammatory disorders
Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor

Letter
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corona RA registry
K L Winthrop, G Citera, D Gold, D Hensloop, C A Connell, A B Shapero, H Shi, A M Oneifte, D A Pappas, H Schulze-Koops

Electronic pages
Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India
L Gupta, D P Misra, V Agarwal, S Balan, V Agarwal

Antirheumatic agents in covid-19: is IL-6 the right target?
P L Capece, P E Lazzerini, L Volterrai, M A Massetti, B Rossetti, G Zanelli, D Bennett, E Bargagli, F Franchi, M Camel, S Valente, L Ciancinini, B Frediani

S Monti, C Montecucco

Online management of rheumatoid arthritis during COVID-19 pandemic
Y Zhang, J Wang, L Zhao, J Xiao, Z Shi

G Figueroa-Parral, C M Camboa-Alonso, D A Galarza-Delgado
e6 Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?  
WXie, Y Wang, Z Zhang

Response to ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
CM Gamboa-Alonso, G Figueroa-Parra, DA Galarza-Delgado

e7 Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
CM Gamboa-Alonso, GFigueroa-Parra, DA Galarza-Delgado

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
CM Gamboa-Alonso, GFigueroa-Parra, DA Galarza-Delgado

e8 To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic
K Parperis

To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic
K Parperis

Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis
FR Spinelli, FCeccarelli, MDi Franco, FConti

Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis
FR Spinelli, FCeccarelli, MDi Franco, FConti

e10 Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
PGuilpain, LLe Bihan, VFoulounge, PTaourel, NPansu, ATJMARI, B Jurg, RLarcher, 
KKleuche, V Le Moing

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
PGuilpain, LLe Bihan, VFoulounge, PTaourel, NPansu, ATJMARI, B Jurg, RLarcher, 
KKleuche, V Le Moing

SMonti, CMSMontecucco

SMonti, CMSMontecucco